On June 30, 2020, the Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV) announced changes in drug reimbursement that is came into force from July 01, 2020. Сhanges mostly affected already existing measures aimed at reducing the price of drugs, and new related drug lists were added.
On July 5, 2020, NHS England launched a new digital service. The new 'Your COVID Recovery' service forms part of NHS efforts to improve access to COVID-19 rehabilitation treatments for those who survived the virus but who have respiratory problems, mental health issues, or other complications.
In June 2020, NICE recommended entrectinib (Rozlytrek, Roche) in the final draft decision for use within the Cancer Drugs Fund, a revolutionary treatment for a number of types of cancers, which is the second histology-independent drug.
On June 25, 2020, the German Society for Hematology and Medical Oncology (DGHO) presented a position paper on how the recommendation of the European Medicines Agency (EMA) concerning genetic testing before cancer therapy with 5-fluorouracil (5-FU) can be implemented in Germany.
On 2 July of 2020, the Dutch Organization for Health Research and Development (ZonMw) announced the ‘Open subsidy round 10’ within their program ‘Good Use of Medicines (GGG)’. There are no restrictions regarding specific themes or disease areas. The deadline for applications is 22 September 2020.
In June 2020, NHS England announced that patients with the deadly genetic condition could benefit from the triple combination treatment includes ivacaftor, tezacaftor, and elexacaftor, produced by Vertex Pharmaceuticals.
On June 26, 2020, the European Medicines Agency (EMA) has published outcomes of the meeting of the Committee for Medicinal Products for Human Use (CHMP). Eight (8) positive opinions on new medicines, one (1) negative opinion, five (5) recommendations on extensions of therapeutic indications, and three (3) withdrawn applications for new medicines were made.
The share of generics in total pharmaceutical supply in Germany rose further: from 67.1% in 2009 to 78.7% in 2019. This emerges from the analysis provided in "Generics in Figures 2019", published by the Pro Generics Association on June 19, 2020.
Within the pilot “Parallel Procedures CBG-ZIN” the innovative drugs become available quicker because it allows obtaining reimbursement in parallel to the registration process. The first drug Rybelsus® (semaglutide tablets) used in type 2 diabetes has completed the pilot.
NHS Digital works with more online consultation suppliers on how to best integrate their products into the NHS App. The goal is that an even greater amount of patients will be able to ask for help and advice from their GP surgery through this route in the future.
On 9 May 2020, the Reimbursement Commission made changes to the Healthcare Implementation Communique. Main drug updates were related to the addition of new cancer drugs to the list of drugs exempt from patient participation shares.
The German Society for Neurology (DGN) has reissued the S1 guideline "Neurosyphilis". The reason is increasing numbers of new infections, which reached a new high of 7,332 cases in 2018 in Germany.
On the 1st of July 2020, the Dutch Healthcare Authority (NZa) has officially adopted tariff decision for new add-on drugs. The list of add-on drugs includes those for treatment of fungal infection, leukemia, non-small cell lung cancer, colorectal cancer, and others.
On June 25, 2020, Danish Medicines Council (Medicinrådet) issued five recommendations (on C1-esterase inhibitor, talazoparib, lorlatinib, pembrolizumab, trastuzumab), two drug recommendations (for breast cancer and melanoma), one protocol for the treatment guide for chronic liver inflammation and one supplement to a treatment guide for chronic rheumatoid arthritis.
The French High Authority for Health (HAS) develops national diagnostic and care protocols whose objective is to guarantee the quality and safety of care delivery within the French setting. In the first half of 2020, national diagnostic and care protocols have been developed for eighteen topics.
On June 25, 2020, the European Medicines Agency (EMA) has recommended Veklury (remdesivir) for treatment COVID-19 pneumonia in adults and adolescents older 12 years who require oxygen supplement. It is the first anti- COVID-19 drug recommended for conditional marketing authorization in the EU.
On June 9, 2020, NHS England announced new online services for diabetes patients. This remote support will supplement the appointments of patients, many of whom have been going on during the pandemic, via video or telephone consultations, and more recently in protected areas under COVID.
By the request of the Austrian Ministry of Health, Horizon Scanning System (HSS) for medicines and vaccines for potential use for COVID-19 treatment is created in Austria with European cooperation. It will be updated monthly. The June update is available at the AIHTA website.